8-K: Aclaris Therapeutics Reports Q4 and Full Year 2024 Financial Results; Provides Corporate Update with Focus on Pipeline Catalysts

Aclaris Therapeutics announces its Q4 and full year 2024 financial results, highlighting a transformative year with multiple clinical catalysts expected in 2025 and a cash runway into 2028.

Summary

• Aclaris Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company anticipates multiple clinical catalysts in 2025 across its pipeline.
• Aclaris acquired worldwide rights (excluding Greater China) to bosakitug (ATI-045) and ATI-052 from Biosion, Inc.
• Phase 2 data for bosakitug in Chinese patients with severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) is expected in the first half of 2025.
• Enrollment in a Phase 2b trial for bosakitug in atopic dermatitis (AD) is on track for the first half of 2025.
• Top-line data from the Phase 2a trial of ATI-2138 in atopic dermatitis is expected in the first half of 2025.
• Aclaris plans to file an Investigational New Drug (IND) application for ATI-052 in the first quarter of 2025.
• Aclaris completed an $80 million private placement in November 2024, extending its cash runway into 2028.
• Dr. Neal Walker has been named Chief Executive Officer, and Hugh Davis, Ph.D., joined as President and Chief Operating Officer.
• William Roberts has been appointed as Senior Vice President, Corporate Communications and Investor Relations.
• As of December 31, 2024, Aclaris had $203.9 million in cash, cash equivalents, and marketable securities, compared to $181.9 million as of December 31, 2023.
• Net loss for the fourth quarter of 2024 was $96.6 million, compared to $1.5 million for the fourth quarter of 2023.
• Net loss for the year ended December 31, 2024, was $132.1 million, compared to $88.5 million for the year ended December 31, 2023.
• Total revenue for the fourth quarter of 2024 was $9.2 million, compared to $17.6 million for the fourth quarter of 2023.
• Total revenue for the year ended December 31, 2024, was $18.7 million, compared to $31.2 million for the year ended December 31, 2023.
• Research and development (R&D) expenses were $9.0 million for the quarter ended December 31, 2024, compared to $26.6 million for the prior year period.
• For the year ended December 31, 2024, R&D expenses were $33.6 million compared to $98.4 million for the year ended December 31, 2023.
• General and administrative (G&A) expenses were $5.0 million for the quarter ended December 31, 2024, compared to $8.2 million for the corresponding prior year period.
• For the year ended December 31, 2024, G&A expenses were $22.2 million compared to $32.4 million for the year ended December 31, 2023.
• Licensing expenses were $8.6 million for the quarter ended December 31, 2024, compared to $5.7 million for the prior year period.
• For the year ended December 31, 2024, licensing expenses were $12.7 million compared to $14.7 million for the year ended December 31, 2023.
• The company recorded $86.9 million of in-process research and development expenses during the quarter and year ended December 31, 2024, related to the in-license of bosakitug (ATI-045) and ATI-052.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss and decreased revenue, it has a strong cash position, promising pipeline catalysts, and key leadership appointments. The forward-looking statements are cautiously optimistic.

Positives

• Aclaris has a strong cash position of $203.9 million, expected to fund operations into 2028.
• The company has multiple clinical catalysts expected in 2025, indicating potential for significant progress in its pipeline.
• The acquisition of worldwide rights to bosakitug (ATI-045) and ATI-052 expands Aclaris's pipeline with potential best-in-class biologic assets.
• The $80 million private placement strengthens the company's financial position.
• Key leadership appointments, including Dr. Neal Walker as CEO and Hugh Davis as President and COO, bring experience and expertise to the company.

Negatives

• Aclaris reported a significant net loss of $96.6 million for the fourth quarter of 2024, compared to a $1.5 million loss in the same period of 2023.
• The company's total revenue decreased to $9.2 million for the fourth quarter of 2024, compared to $17.6 million for the fourth quarter of 2023.
• The company recorded a one-time $86.9 million in-process research and development charge related to the acquisition of bosakitug (ATI-045) and ATI-052.

Risks

• The success of Aclaris's development programs depends on the outcome of clinical trials, which are inherently uncertain.
• Aclaris relies on third parties, including CTTQ, for the development and commercialization of some of its product candidates, which could be subject to delays or other issues.
• The company's ability to enter into strategic partnerships on commercially reasonable terms is uncertain.
• Macroeconomic conditions could impact Aclaris's financial performance and ability to raise capital.

Future Outlook

Aclaris expects multiple clinical catalysts in 2025 and believes its cash, cash equivalents, and marketable securities will be sufficient to fund its operations into 2028.

Management Comments

• Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris, stated that 2024 was a transformative year that has positioned Aclaris with multiple clinical catalysts expected in 2025 across our expanded pipeline.
• Dr. Walker also mentioned excitement about the upcoming Phase 2 data for bosakitug in both severe asthma and chronic rhinosinusitis with nasal polyps anticipated from our partner CTTQ, which we expect will provide important insights into our future development of bosakitug in respiratory diseases.

Industry Context

Aclaris is focused on developing novel drug candidates for immuno-inflammatory diseases, a competitive area with significant unmet needs. The acquisition of bosakitug and ATI-052 positions Aclaris to compete with other companies developing biologics for these indications.

Comparison to Industry Standards

• Aclaris's cash runway into 2028 provides a competitive advantage compared to smaller biotech companies that frequently need to raise capital.
• The focus on immuno-inflammatory diseases aligns with a broader industry trend towards developing targeted therapies for these conditions.
• Companies like Amgen, Regeneron, and Sanofi are major players in the immuno-inflammatory space, and Aclaris's success will depend on its ability to differentiate its product candidates.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the strong cash position and pipeline progress.
• Employees may be positively impacted by the new leadership appointments and the company's focus on growth.
• Patients with immuno-inflammatory diseases may benefit from the development of new treatment options.
• The company's suppliers and partners may benefit from its continued investment in research and development.

Next Steps

• Aclaris plans to initiate enrollment in a Phase 2b trial for bosakitug in atopic dermatitis in the first half of 2025.
• The company expects top-line data from its Phase 2a trial of ATI-2138 in atopic dermatitis in the first half of 2025.
• Aclaris plans to file an Investigational New Drug (IND) application for ATI-052 in the first quarter of 2025.
• Aclaris expects Phase 2 data for bosakitug in Chinese patients with severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in the first half of 2025.

Key Dates